Acalabrutinib 

MAFAcalabrutinib Capsule 100 mg

1) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.
2) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy.
3) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

MAFAcalabrutinib Tablet 100 mg

1) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.
2) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy.
3) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

MSHLAcalabrutinib Capsule 100 mg

1) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.
2) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy.
3) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

MSHLAcalabrutinib Capsule 100 mg

Acalabrutinib in combination with obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.

MSHLAcalabrutinib Tablet 100 mg

1) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.
2) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy.
3) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

MSHLAcalabrutinib Tablet 100 mg

Acalabrutinib in combination with obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.